SCHEDULE: Goldman Sachs Discloses 0.0% Stake in 2SEVENTY BIO
Beneficial Ownership Report
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a 0.0% beneficial ownership stake in 2SEVENTY BIO, INC. as of June 30, 2025.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly filed an Amendment No. 1 to Schedule 13G.
- The filing pertains to the beneficial ownership of Common Stock, par value $0.0001 per share, of 2SEVENTY BIO, INC.
- As of June 30, 2025, the reporting persons collectively beneficially own 308 shares of 2SEVENTY BIO, INC., representing 0.0% of the class.
- Goldman Sachs Group, Inc. is classified as a parent holding company (HC) and a corporation (CO).
- Goldman Sachs & Co. LLC is classified as a broker or dealer (BD), an investment adviser (IA), and an other (OO) type of reporting person.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine regulatory disclosure of a very small, passive ownership stake (0.0%). It provides factual information without indicating any positive or negative sentiment towards the issuer's performance or prospects.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or the reporting entities' future investment intentions beyond the scope of this specific holding.
Industry Context
This Schedule 13G filing is a routine disclosure by a large institutional investor, Goldman Sachs, indicating its passive beneficial ownership in 2SEVENTY BIO, INC. Such filings are common for investment firms that hold securities in the ordinary course of business and do not intend to influence or change control of the issuer. The reported 0.0% stake is negligible and typical for a large diversified financial institution's minor holdings.
Comparison to Industry Standards
- This filing is a standard Schedule 13G, which is a common regulatory disclosure for institutional investors. The reported 0.0% ownership is a de minimis stake, indicating no significant investment position or strategic intent in 2SEVENTY BIO, INC. by Goldman Sachs.
- Compared to other institutional holdings in biotechnology companies, a 0.0% stake is not indicative of a significant investment thesis or active management. Larger, more strategic stakes (typically 5% or more, triggering a Schedule 13D filing) would signal a more material interest or potential influence.
Stakeholder Impact
- Shareholders: Minimal impact due to the negligible 0.0% ownership stake reported by a large institutional investor, indicating no significant change in institutional interest or control.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-16 | Date new Power of Attorney was granted by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
| 2025-07-17 | Date of filing of the Schedule 13G and Joint Filing Agreement. |
| 2026-07-16 | Expiration date of the current Power of Attorney. |
Keywords
Goldman Sachs, 2SEVENTY BIO, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.